Risk factors and primary prevention trials for type 1 diabetes

International Journal of Biological Sciences

Volumn 9, Issue 6, 2013, Pages 666-679

  Wu, Yan Ling ^a   Ding, Yan Ping ^a   Gao, Jian ^a   Tanaka, Yoshimasa ^b   Zhang, Wen ^c  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b KYOTO UNIVERSITY   (Japan)

^c ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

C kit; Diabetes; Environmental factors; Epigenetics; Pathogenesis; PD 1; Prevention trials; Susceptibility gene; Type

Indexed keywords

HLA ANTIGEN; INSULIN;

ANIMAL; ARTICLE; BABY FOOD; BIOSYNTHESIS; C-KIT; CHILD; CLINICAL TRIAL (TOPIC); ENVIRONMENT; ENVIRONMENTAL FACTORS; EPIGENETICS; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MILK; PATHOGENESIS; PD-1; PRESCHOOL CHILD; PREVENTION TRIALS.; RISK FACTOR; SUSCEPTIBILITY GENE; TWINS;

C-KIT; ENVIRONMENTAL FACTORS; EPIGENETICS; PATHOGENESIS; PD-1; PREVENTION TRIALS.; SUSCEPTIBILITY GENE; TYPE 1 DIABETES;

ANIMALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DISEASES IN TWINS; ENVIRONMENT; EPIGENOMICS; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; INFANT; INFANT FOOD; INSULIN; MILK; RISK FACTORS;

EID: 84880587356     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6610     Document Type: Article

References (142)

1. Jönsson L, Hallström I, Lundqvist A. "The logic of care"-parents' perceptions of the educational process when a child is newly diagnosed with type 1 diabetes. BMC Pediatr. 2012; 12: 165.
2. Rankin D, Cooke DD, Elliott J, et al. Supporting self-management after attending a structured education programme: a qualitative longitudinal investigation of type 1 diabetes patients' experiences and views. BMC Public Health. 2012; 12: 652.
3. Alderson P, Sutcliffe K, Curtis K. Children as partners with adults in their medical care. Arch Dis Child. 2006; 91: 300-303.
4. Hawa MI, Beyan H, Buckley LR, et al. Impact of genetic and non-genetic factors in type 1diabetes. Am J Med Genet. 2002; 115: 8-17.
5. Pociot F, McDermott MF. Genetics of type 1diabetes mellitus. Genes Immun. 2002; 3: 235-249.
6. Vauzelle-Kervroëdan F, Delcourt C, Forhan A, et al. Analysis of mortality in French diabetic patients from death certificates: a comparative study. Diabetes Metab. 1999; 25: 404-411.
7. Barker JM, Barriga KJ, Yu L, et al. Diabetes Autoimmunity Study in the Young. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab. 2004; 89: 3896-3902.
8. Nerup J, Platz P, Andersen OO, et al. HL-A antigens and diabetes mellitus. Lancet. 1974; 2(7885): 864-866.
9. Raum D, Awdeh Z, Yunis EJ, Alper CA, Gabbay KH. Extended major histocompatibility complex haplotypes in Type 1 diabetes mellitus. J Clin Invest. 1984; 74: 449-454.
10. Noble JA, Valdes AM, Cook M, et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecularanalysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996; 59: 1134-1148.
11. Larsen CE, Alper CA. The genetics of HLA-associated disease. Curr Opin Immunol. 2004; 16: 660-667.
12. Singal DP, Blajchman MA. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes. 1973; 22: 429-432.
13. Cudworth AG, Woodrow JC. Evidence for HLA-linked genes in 'juvenile' diabetes mellitus. Br Med J. 1975; 3: 133-135.
14. Thomsen M, Platz P, Andersen OO, et al. MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev. 1975; 22: 125-147.
15. Thomson G. HLA disease associations: models for insulin dependent diabetes mellitus and the study of complex human genetic disorders. Annu Rev Genet. 1988; 22: 31-50.
16. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987; 329: 599-604.
17. Bingley PJ, Gale EA. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006; 49: 881-890.
18. Bell GI, Horita S, Karam JH. A polymorphiclocus near the human insulin gene is associatedwith insulin-dependent diabetes mellitus. Diabetes. 1984; 33: 176-183.
19. Nisticò L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996; 5: 1075-1080.
20. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004; 36: 337-338.
21. Hirschhorn JN. Genetic epidemiology of type 1 diabetes. Pediatr Diabetes. 2003; 4: 87-100.
22. Dorman JS, Bunker CH. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiol Rev. 2000; 22: 218-227.
23. Bennett ST, Wilson AJ, Esposito L. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. Nat Genet. 1997; 17: 350-352.
24. Undlien DE, Hamaguchi K, Kimura A. Type 1 diabetes susceptibility associated with polymorphism in the insulin gene region: a study of blacks, Caucasians, and orientals. Diabetologia. 1994; 37: 745-749.
25. Kantárová D, Buc M. Genetic susceptibility to type 1 diabetes mellitus in humans. Physiol Res. 2007; 56: 255-266.
26. Burn GL, Svensson L, Sanchez-Blanco C, et al. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 2011; 585: 3689-3698.
27. Gjörloff-Wingren A, Saxena M, Williams S, et al. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol. 1999; 29: 3845-3854.
28. Cohen S, Dadi H, Shaoul E, et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood. 1999; 93: 2013-2024.
29. Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev. 2008; 29: 697-725.
30. Hewagama A, Richardson B. The genetics and epigenetics of autoim-mune diseases. J Autoimmun. 2009; 33: 3-11.
31. Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol. 2001; 2: 769-770.
32. Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev. 2013; 29: 8-18.
33. Volkmar M, Dedeurwaerder S, Cunha DA, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J. 2012; 31: 1405-1426.
34. Buzzetti R, Di Pietro S, Giaccari A, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007; 30: 932-938.
35. Rakyan VK, Beyan H, Down TA, et al. Identification of type 1 diabe-tes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011; 7: e1002300.
36. Fradin D, Le Fur S, Mille C, et al. Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes. PLoS One. 2012; 7: e36278.
37. Bell CG, Teschendorff AE, Rakyan VK, et al. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics. 2010; 3: 33.
38. Akirav EM, Lebastchi J, Galvan EM, et al. Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci USA. 2011; 108: 19018-19023.
39. Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev. 2005; 21: 416-433.
40. Miao F, Smith DD, Zhang L, et al. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes. 2008; 57: 3189-3198.
41. Tikoo K, Meena RL, Kabra DG, et al. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol. 2008; 153: 1225-1231.
42. Brasacchio D, Okabe J, Tikellis C, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009; 58: 1229-1236.
43. Sebastiani G, Grieco FA, Spagnuolo I, et al. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev. 2011; 27: 862-866.
44. Hezova R, Slaby O, Faltejskova P, et al. MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2010; 260: 70-74.
45. Fernandez-Valverde SL, Taft RJ, Mattick JS. Micro RNAs in β-cell biology, insulin resistance, diabetes and its complications. Diabetes. 2011; 60: 1825-1831.
46. Hirschhorn JN. Genetic epidemiology of type 1 diabetes. Pediatr Diabetes. 2003; 4: 87-100.
47. Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ. 1999; 318: 698-702.
48. Petersen JS, Kyvik KO, Bingley PJ, et al. Population based study of prevalence of islet cell autoantibodies in monozygotic and dizygotic Danish twin pairs with insulin dependent diabetes mellitus. BMJ. 1997; 314: 1575-1579.
49. Hawa M, Rowe R, Lan MS, et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes. 1997; 46: 1270-1275.
50. Kumar D, Gemayel NS, Deapen D, et al. North-American twins with IDDM. Genetic, etiological, and clinical significance of disease concordance according to age, zygosity, and the interval after diagnosis in first twin. Diabetes. 1993; 42: 1351-1363.
51. Kyvik KO, Green A, BeckNielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ. 1995; 311: 913-917.
52. Hyoty H, Hiltunen M, Reuranen A. Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children with a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measle s-rubella vaccine in Finland. Diabetologia. 1993; 41: 40-46.
53. McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet. 1992; 340: 414-415.
54. Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011; 91:79-118.
55. Hyoty H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002; 45: 1353-1361.
56. Yeung WC, Rawlinson WD, Craig M. Enterovirus infection and type 1 diabetes mellitus: Systematic review and meta-analysis of observational molecular studies. BMJ. 2011; 342: 335.
57. Hyöty H, Hiltunen M, Knip M, Laakkonen M, et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes. 1995; 44: 652-657.
58. Chiodini RJ, Van Kruiningen HJ, Merkal RS. Ruminant paratuberculosis (Johne's disease): the current status and future prospects. Cornell Vet. 1984; 74: 218-262.
59. Di Sabatino A, Paccagnini D, Vidali F, et al. Detection of Mycobacterium avium subsp. paratuberculosis (MAP)-specific IS900 DNA and antibodies against MAP peptides and lysate in the blood of Crohn's disease patients. Inflamm Bowel Dis. 2011; 17: 1254-1255.
60. Rosu V, Ahmed N, Paccagnini D, et al. Specific immunoassays confirm association of Mycobacterium avium Subsp. paratuberculosis with type-1 but not type-2 diabetes mellitus. PLoS One. 2009; 4: e4386.
61. Ellingson JL, Anderson JL, Koziczkowski JJ, et al. Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by two culture methods and PCR. J Food Prot. 2005; 68: 966-972.
62. Cossu A, Rosu V, Paccagnini D, et al. MAP3738c and MptD are specific tags of Mycobacterium avium subsp. paratuberculosis infection in type I diabetes mellitus. Clin Immunol. 2011; 141: 49-57.
63. Sechi LA, Rosu V, Pacifico A, et al. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin Vaccine Immunol. 2008; 15: 320-326.
64. Rani PS, Sechi LA, Ahmed N. Mycobacterium avium subsp. paratuberculosis as a trigger of type-1 diabetes: destination Sardinia, or beyond? Gut Pathog. 2010; 2: 1.
65. Paccagnini D, Sieswerda L, Rosu V, et al. Linking chronic infection and autoimmune diseases: Mycobacterium avium subspecies paratuberculosis, SLC11A1 polymorphisms and type-1 diabetes mellitus. PLoS One. 2009; 4: e7109.
66. Sechi LA, Paccagnini D, Salza S, et al. Mycobacterium avium subspecies paratuberculosis bacteremia in type 1 diabetes mellitus: an infectious trigger? Clin Infect Dis. 2008; 46: 148-149.
67. Masala S, Paccagnini D, Cossu D, et al. Antibodies recognizing mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. PLoS One. 2011; 6:26931.
68. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007; 104: 17040-17045.
69. Okazaki T, Maeda A, Nishimura H, et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001; 98: 13866-13871.
70. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002; 20: 29-53.
71. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 2002; 14: 779-782.
72. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2: 116-126.
73. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198: 63-69.
74. Nielsen C, Hansen D, Husby S, et al. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003; 62: 492-497.
75. Kwon NS, Lee SH, Choi CS, et al. Nitric oxide generation from streptozotocin. FASEB J. 1994; 8: 529-533.
76. Won TJ, Jung YJ, Kwon SJ, et al. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes. Arch Pharm Res. 2010; 33: 1825-1833.
77. Yoshida T, Jiang F, Honjo T, et al. PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci USA. 2008; 105: 3533-3538.
78. Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33: 2706-2716.
79. Wang J, Yoshida T, Nakaki F, et al. Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA. 2005; 102: 11823-11828.
80. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198: 63-69.
81. Yashpal NK, Li J, Wang R. Characterization of c-Kit and nestin expression during islet cell development in the prenatal and postnatal rat pancreas. Dev Dyn. 2004; 229: 813-825.
82. Li J, Quirt J, Do HQ, et al. Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas. Am J Physiol Endocrinol Metab. 2007; 293: E475-483.
83. Rachdi L, Ghazi LE, Bemex F, et al. Expression of the receptor tyrosine kinase KIT in mature β-cells and in the pancreas in development. Diabetes. 2001; 50: 2021-2028.
84. Wang R, Li J, Yashpal NK. Phenotypic analysis of c-kit expression in epithelial monolayers derived from postnatal rat pancreatic islets. J Endocrinol. 2004; 182: 113-122.
85. Welsh M, Anneren C, Lindholm C, Kriz V, Oberg-Welsh C. Role of tyrosine kinase signaling for beta-cell replication and survival. Ups J Med Sci. 2000; 105: 7-15.
86. Yashpal NK, Li J, Wang R. Characterization of c-kit and nestin expression during islet cell development in the prenatal and postnatal rat pancreas. Dev Dyn. 2004; 229: 813-825.
87. Feng ZC, Li J, Turco BA, et al. Critical role of c-Kit in beta cell function: increased insulin secretion and protection against diabetes in a mouse model. Diabetologia. 2012; 55: 2214-2225.
88. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289: 2254-2264.
89. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent develop-ments. BMJ. 2004; 328(7442): 750-754.
90. Knip M, Virtanen SM, Akerblom HK. Infant feeding and the risk of type 1 diabetes. Am J Clin Nutr. 2010; 91: 1506S-1513S.
91. Akerblom HK, Savilahti E, Saukkonen TT, et al. The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diabetes Metab Rev. 1993; 9: 269-278.
92. Gerstein HC. Cow's milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care. 1994; 17: 13-19.
93. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010; 363: 1900-1908.
94. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes. 2007; 8: 117-137.
95. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012; 166: 608-614.
96. Ziegler AG, Schmid S, Huber D, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. J Am Med Assoc. 2003; 290: 1721-1728.
97. Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003; 290: 1713-1720.
98. Pastore MR, Bazzigaluppi E, Belloni C, et al. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab. 2003; 88: 162-165.
99. Takiishi T, Van Belle T, Gysemans C, et al. Effects of vitamin D on antigen-specific and non-antigen-specific immune modulation: relevance for type 1 diabetes. Pediatr Diabetes. 2013; 14: 81-89.
100. Simpson M, Brady H, Yin X, et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011; 54: 2779-2788.
101. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child. 2008; 93: 512-517.
102. Gabbay MA, Sato MN, Finazzo C, et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med. 2012; 166: 601-607.
103. Walter M, Kaupper T, Adler K, et al. No effect of the 1alpha, 25-dihydroxy vitamin D3 on β-cell residual function and insulin re-quirement in adults with new-onset type 1 diabetes. Diabetes Care. 2010; 33: 1443-1448.
104. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; IMDIAB Group. No protective effect of calcitriol on beta-cell function in re-cent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care. 2010; 33(9): 1962-1963.
105. Lazarow A. Protection against alloxan diabetes. Anat Rec. 1947; 97: 353.
106. Dulin WE, Wyse BM. Studies of ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes. 1969; 18: 459-466.
107. Yamada K, Nonaka K, Hanafusa T, et al. Preventive and therapeutic aspects of large dose nicotinamide injections on diabetes associated with insulitis: an observation in non-obese diabetic (NOD) mice. Diabetes. 1982; 31: 749-753.
108. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (EN-DIT): a ran-domized controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004; 363: 925-931.
109. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 2010; 59: 2087-2093.
110. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013; 9: 92-103.
111. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 1993; 341: 927-928.
112. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002; 346: 1685-1691.
113. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28: 1068-1076.
114. Vehik K, Cuthbertson D, Ruhlig H, et al. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care. 2011; 34: 1585-1590.
115. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care. 2004; 27: 2348-2355.
116. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008; 372: 1746-1755.
117. Ryhänen SJ, Härkönen T, Siljander H, et al. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetes Care. 2011; 34: 1383-1388.
118. Thrower SL, James L, Hall W, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol. 2009; 155: 156-165.
119. Skyler JS. Primary and secondary prevention of Type 1 diabetes. Diabet Med. 2013; 30:161-169.
120. Carel JC, Boitard C, Eisenbarth G, et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun. 1996; 9: 739-745.
121. Eisenbarth GS. Banting Lecture 2009. An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes. 2010; 59: 759-774.
122. Skyler JS and the Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008; 1150: 190-196.
123. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28: 1068-1076.
124. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabites Care. 2010; 33: 1004-1008.
125. Matthews JB, Staeva TP, Bernstein PL, et al. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol. 2010; 160: 176-184.
126. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301: 1573-1579.
127. Michels AW, Nakayama M. The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010; 17: 329-334.
128. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008; 57: 1084-1092.
129. Steenkiste A, Valdes AM, Feolo M, et al. 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes. Tissue Antigens. 2007; 69: 214-225.
130. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insu-lin-dependent diabetics before insulin treatment. Science. 1983; 222: 1337-1339.
131. Achenbach P, Koczwara K, Knopff A, et al. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004; 114: 589-597.
132. Lee KH, Wucherpfennig KW, Wiley DC. Structure of a human insulin peptide/ HLA-DQ8 complex and susceptibility to type 1 diabetes. Na-ture Immunology. 2001; 2: 501-507.
133. Stadinski BD, Zhang L, Crawford F, et al. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA. 2010; 107: 10978-10983.
134. Matthews JB, Staeva TP, Bernstein PL, et al. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol. 2010; 160: 176-184.
135. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301: 1573-1579.
136. Michels AW, Nakayama M. The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010; 17: 329-334.
137. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008; 57: 1084-1092.
138. Steenkiste A, Valdes AM, Feolo M, et al. 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes. Tissue Antigens. 2007; 69: 214-225.
139. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983; 222: 1337-1339.
140. Achenbach P, Koczwara K, Knopff A, et al. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004; 114: 589-597.
141. Lee KH, Wucherpfennig KW, Wiley DC. Structure of a human insulin peptide/ HLA-DQ8 complex and susceptibility to type 1 diabetes. Nature Immunology. 2001; 2: 501-507.
142. Stadinski BD, Zhang L, Crawford F, et al. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA. 2010; 107: 10978-10983.